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Platinum salts are active against metastatic triple negative breast cancer (mTNBC), and biomarkers 
to predict their effectiveness are urgently needed. In recent years, the neutrophil-to-lymphocyte ratio 
(NLR) and the platelet-to-lymphocyte ratio (PLR) have emerged as prognostic biomarkers in many 
malignancies, but their predictive role in platinum-treated mTNBC patients remains unexplored. We 
performed a retrospective, single centre study to evaluate the association between baseline NLR or 
PLR and progression free survival (PFS) of mTNBC patients treated with platinum-based chemotherapy. 
As a control population, we analysed data from patients with hormone receptor-positive HER2-
negative (HR+ HER2−) metastatic breast cancer. Among 57 mTNBC patients treated with the 
carboplatin-paclitaxel or carboplatin-gemcitabine combination, high NLR and PLR were associated 
with significantly lower PFS at both univariate and multivariable analysis. Conversely, we did not find 
a significant association between NLR or PLR and the PFS of 148 patients in the control population. 
Our findings suggest that the NLR and PLR are predictive of benefit from platinum-containing 
chemotherapy specifically in mTNBC patients. If validated in larger prospective studies, these easy-
to-measure parameters could be combined with emerging predictive biomarkers, such as BRCA 1/2 
mutations, to improve the selection of mTNBC patients more likely to benefit from platinum-based 
chemotherapy.
Breast cancer (BC) is the most common malignancy among women and also one of the leading causes of 
cancer-related death1. Metastatic triple negative breast cancer (mTNBC) accounts for 10–20% of metastatic BC 
(mBC) cases, and is characterized by an aggressive course, the lack of therapeutic targets and high lethality2,3. 
Even in recently published prospective trials, median progression free survival (PFS) and overall survival (mOS) 
did not exceed 6 months and 12–18 months, respectively4,5.
Cytotoxic chemotherapy (ChT) remains the mainstay of treatment for mTNBC, with taxane and platinum 
salts being among the most effective compounds when used alone, or in combination with bevacizumab or other 
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chemotherapeutical agents4–9. In a recent randomized study, carboplatin demonstrated superior activity com-
pared to docetaxel in mTNBC patients bearing germline mutations in BRCA1 or BRCA2 genes, thus suggesting 
that platinum compounds should be preferred treatment options in this patient population6. While such results 
await confirmation in larger studies, new predictive biomarkers are needed that are low-cost, routinely assessable 
with standardized techniques, well reproducible across different laboratories, and capable of predicting benefit 
from platinum-based ChT.
Many evidences highlight the importance of immune system activation in TNBC control: first, 
tumor-infiltrating lymphocytes (TILs) and other immune markers correlate with higher rates of pathological 
complete response (pCR), as well as with better patient disease-free survival (DFS) and OS, after neoadjuvant 
ChT10–13; second, the programmed death 1 (PD-1) inhibitor pembrolizumab and the PD-1 ligand (PD-L1) 
inhibitor atezolizumab are active in subgroups of heavily pre-treated TNBC patients14–16; lastly, combining 
nab-paclitaxel with atezolizumab has shown promising clinical activity in TNBC17,18, and taxanes-atezolizumab 
combinations are being evaluated in larger prospective trials [NCT02425891; NCT03125902].
Recent studies have revealed the prognostic role of parameters that reflect systemic inflammation or the status 
of antitumor immunity, such as the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio 
(PLR), in different solid malignancies, including colorectal, renal and lung carcinomas19,20. High NLR has also 
been associated with an increased risk of death in heterogeneous BC patient populations21, including patients 
with limited-stage TNBC22,23. However, none of these studies specifically assessed the role of NLR in mTNBC 
and, even in those studies including different proportions of patients with mBC (4.2–13.9%), subgroup analyses 
in specific tumor biology subgroups, or based on the type of ChT, were not reported24–28.
In this work, we assessed for the first time the potential role of NLR and PLR as biomarkers predictive of PFS 
in mTNBC patients treated with platinum-based ChT. As a control population, we analysed data from patients 
with hormone receptor-positive HER2-negative (HR+ HER2−) mBC treated with the same platinum-containing 
regimens. To discriminate between a predictive and a purely prognostic role of these parameters, we also evalu-
ated patient OS.
Results
Patient characteristics. Between July 2007 and July 2017, 62 mTNBC patients were treated at our 
Institution with platinum-based ChT combinations. Among these patients, 57 fulfilled the inclusion criteria and 
were evaluable for the biomarkers of interest. At the moment of data lock and analysis, 53 (93%) patients had 
progressed and 48 (84%) had died.
Characteristics of evaluated patients are described in Table 1. Median age among TNBC patients was 56 years 
(range 33.7–78.9). Most patients (84%) received carboplatin-paclitaxel ChT, while the remaining ones (16%) were 
treated with the carboplatin-gemcitabine combination. All mTNBC patients received platinum-containing ChT 
as their first- (88%) or second-line (12%) treatment.
In the control population of HR+ HER2− patients, median age was 58 years (range 29.8–79.3); 
most patients (75.7%) were treated with carboplatin-paclitaxel and the remaining ones (24.3%) received 
carboplatin-gemcitabine. Of these patients, 70.3% received platinum-containing ChT as their first- or second-line 
therapy.
Impact of NLR and PLR on PFS. Median PFS in the TNBC population was 204 days. Higher neutrophils 
(4000/µl) were associated with non-significantly lower PFS (p = 0.081), while platelets above 300000/µl or lym-
phocytes below 1500/µl correlated with significantly shorter PFS (p = 0.041 and p = 0.005, respectively) (Fig. S1).
TNBC
ER/PgR-positive 
HER2-negative
N. pts 57 148
Median age (years, range) 56 (33.7–78.9) 58 (29.8–79.3)
Previous taxane exposure
   Yes 43 (75.4%) 102 (68.9%)
   No 14 (24.6%) 46 (31.1%)
N. chemotherapy line
   1st–2nd 57 (100%) 104 (70.3%)
   >2nd 0 (0%) 44 (29.7%)
N. disease sites:
   1–2 sites 36 (63.2%) 88 (59.5%)
   >2 sites 21 (36.8%) 60 (40.5%)
Presence of visceral disease 37 (65%) 99 (66.9%)
Type of treatment
   paclitaxel 48 (84.2%) 112 (75.7%)
   gemcitabine 9 (15.8%) 36 (24.3%)
Maintenance therapy 14 (24.6%) 65 (43.9%)
Table 1. Characteristics of patients with mTNBC and the HR+ mBC control population.
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We then investigated the potential predictive role of NLR and PLR. Based on previous studies, we chose a 
NLR threshold of 2.5 and a PLR threshold of 20021,29. Both NLR and PLR were inversely associated with patient 
age (p < 0.001 and p = 0.048, respectively), while they did not correlate with previous taxane exposure (p = 0.076 
and p = 0.68, respectively), presence of visceral disease (p = 0.9 and p = 0.6, respectively), type of ChT received 
(p = 0.48 and p = 0.7, respectively) and number of metastatic sites (p = 0.22 and p = 0.39, respectively) (Table 2). 
Finally, high NLR correlated with lower probability of receiving maintenance ChT (p = 0.017), while PLR did not 
(p = 0.097).
Median PFS was 304 days in patients with NLR < 2.5 and 158 days in those with NLR ≥ 2.5 (HR 3.25, 95% 
CI 1.72–6.25; p < 0.001) (Fig. 1A). Similar results were obtained by choosing a threshold of 3.3 (274 vs 148 days, 
p < 0.0001) or 2 (309 vs 186 days, p = 0.0015) (data not shown). Regarding the PLR, PFS was longer in patients 
with baseline PLR < 200 as compared to PLR ≥ 200 (HR 2.75, 95% CI 1.52–4.99; p < 0.001) (Fig. 1B). Baseline 
LMR ≥ 4.5 was also associated with significantly better PFS in TNBC patients, although the association was less 
strong than in the case of NLR and PLR (HR 2.22, 95% CI 1.22–4.05, p = 0.009; data not shown).
When the same parameters were evaluated before the administration of the third treatment cycle, NLR < 2.5 
was still associated with reduced risk of disease progression (140 vs 262 days, p < 0.001), while PLR < 200 was not 
(259 vs 204 days, p = 0.48) (data not shown).
In the control population of HR+ HER2− mBC patients, mPFS was 220 days. Baseline higher NLR and PLR 
were non-significantly associated with the risk of disease progression (p = 0.21 and p = 0.29) (Fig. 1C and D).
Independent predictive role of NLR and PLR on PFS. Factors associated with the risk of disease pro-
gression in mTNBC were: previous exposure to taxanes, the presence of visceral metastases, having received 
maintenance ChT, NLR ≥ 2.5 and PLR ≥ 200 (Fig. 2A). As previously described27, NLR and PLR positively cor-
related with each other (Pearson coefficient regression = 0.49; p < 0.001); therefore, only one of these parameters 
was evaluated at multivariable analysis.
In the multivariable model including NLR as a covariate, NLR ≥ 2.5 was associated with significantly lower 
PFS (HR 2.65; p = 0.004), while other covariates were not statistically significantly associated with PFS (Fig. 2B). 
When we tested PLR at multivariable analysis, PLR ≥ 200 was independently associated with poorer patient prog-
nosis (HR 2.33; p = 0.007), while the other covariates were not, with the exception of maintenance ChT, which 
correlated with reduced risk of progression (HR 0.45; p = 0.027) (data not shown).
Impact of peripheral blood parameters on OS. Median OS was 483 days in mTNBC patients and 653 
days in the control population of HR+ HER2− patients.
In mTNBC patients, mOS was significantly longer in patients with NLR < 2.5 compared to those with 
NLR ≥ 2.5 (p = 0.01), while PLR values were not associated with mOS (p = 0.14) (Fig. 3, upper panels). In HR+ 
HER2− BC patients, both NLR < 2.5 and PLR < 200 were associated with significantly better mOS (p = 0.023 and 
p = 0.003, respectively) (Fig. 3, lower panels).
At univariate analysis, factors associated with worse OS in mTNBC patients were NLR ≥ 2.5 and having 
received gemcitabine in combination with carboplatin, while maintenance ChT correlated with better PFS 
Total (n = 57) NLR <2.5 (n = 25) NLR ≥2.5 (n = 32)
p value
PLR <200 (n = 34) PLR ≥200 (n = 23)
p valueN (%) N (%) N (%) N (%) N (%)
Pts age
   <50 yrs 21 (36.8%) 3 (5.2%) 18 (31.6%)
<0.001
9 (15.8%) 12 (21%)
0.048
   >50 yrs 36 (63.2%) 22 (38.6%) 14 (24.6%) 25 (43.9%) 11 (19.3%)
Previous taxane
   Yes 43 (75.4%) 16 (28%) 27 (47.4%)
0.076
25 (43.8%) 18 (31.6%)
0.68
   No 14 (24.6%) 9 (15.8%) 5 (8.8%) 9 (15.8%) 5 (8.8%)
Visceral disease
   Yes 37 (64.9%) 16 (28%) 21 (36.8%)
0.9
23 (40.3%) 14 (24.6%)
0.6
   No 20 (35.1%) 9 (15.8%) 11 (19.4%) 11 (19.3%) 9 (15.8%)
N. metastatic sites
   1–2 36 (63.2%) 18 (31.6%) 18 (31.6%)
0.22
23 (40.3%) 13 (22.8%)
0.39
   >2 21 (36.8%) 7 (12.3%) 14 (24.5%) 11 (19.3%) 10 (17.6%)
ChT type
   Taxane 48 (84.2%) 20 (35.1%) 28 (49.1%)
0.48*
28 (49.1%) 20 (35.1%)
0.7*
   Gemcitabine 9 (15.8%) 5 (8.8%) 4 (7%) 6 (10.5%) 3 (5.3%)
Maintenance ChT
   Yes 14 (24.6%) 10 (17.6%) 4 (7%)
0.017
11 (19.3%) 3 (5.3%)
0.097
   No 43 (75.4%) 15 (26.3%) 28 (49.1%) 23 (40.3%) 20 (35.1%)
Table 2. Characteristics of mTNBC patients by NLR and PLR. Pts = patients; ChT = chemotherapy. *Fisher’s 
exact test.
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(Fig. 4A). At multivariable analysis, NLR ≥ 2.5 and gemcitabine treatment were independently associated with 
worse outcomes (Fig. 4B).
In the control population, factors associated with lower OS were: NLR ≥ 2.5, presence of visceral disease, 
previous taxane exposure and more advanced (>2nd) treatment lines, while having received maintenance ther-
apy correlated with lower risk of death (Fig. S2, upper panel). At multivariable analysis, high NLR and visceral 
involvement were independently associated with lower survival, while maintenance treatment correlated with 
better outcome (Fig. S2, lower panel).
Impact of germline BRCA 1/2 mutations on TNBC patient PFS. Among mTNBC patients included 
in our study, only 19 had undergone analysis of germline mutations of the BRCA1/2 genes. Of them, 6 were car-
riers of a pathogenic germline BRCA1/2 mutation, while the remaining 13 patients had wild-type BRCA1/2 gene. 
Median PFS was 126 days in carriers of BRCA1/2 mutations and 163 days in non-mutated ones (HR = 1.09, 50% 
CI 0.38–3.12, p = 0.87).
Discussion
Although platinum-based ChT is active against mTNBC, many patients fail to respond, and no biomark-
ers are currently available to predict treatment effectiveness. In this study, we found for the first time an asso-
ciation between higher NLR or PLR and worse PFS in mTNBC patients receiving carboplatin-paclitaxel 
or carboplatin-gemcitabine, but not in a control population of HR+ HER2− patients treated with the same 
regimens.
The fact that specific blood cell populations reflect the inflammatory/immune contexture is quite a 
well-established concept. Indeed, high neutrophils can be associated with systemic inflammation or immune 
suppression30; high platelets reflect systemic inflammation as well, but can be also associated with increased meta-
statization of neoplastic cells via platelet clots30–32; finally, low lymphocyte counts can be associated with impaired 
activation of adaptive immunity or poor nutritional status33,34. In this study, the association between clinical 
Figure 1. Kaplan-Meier curves of progression free survival (PFS) of TNBC and HR+ mBC patients according 
to baseline NLR (A and C) and PLR (B and D).
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outcomes and NLR/PLR was stronger than in the case of individual cell counts. This is not surprising, since 
parameter combinations are more stable to changes in single parameters (e.g. neutrophils or platelets can increase 
during acute infections or glucocorticoid administration) and may capture more aspects of the tumor-immune 
system interplay. Notably, the HRs associated to NLR and PLR at multivariable analysis for PFS were similar, and 
these parameters also correlated with each other. This suggests that both NLR and PLR well reflect the inflamma-
tory/immune contexture in mTNBC, and may be redundant as predictive biomarkers.
In TNBC patients, higher NLR correlated with lower OS, but the association was weaker than in the case of 
PFS; moreover, no statistically significant association was found between PLR and OS. These results can be due to 
the fact that, different from PFS, OS is affected by the whole treatment course, including therapies administered 
after platinum-based ChT; therefore, the association between NLR/PLR and PFS during platinum-based ChT 
could be diluted by subsequent treatments for which the same parameters are not predictive.
Conversely, both NLR and PLR correlated with lower OS in the control population of HR+ HER2− mBC 
patients, despite the fact that they were not predictive of PFS during platinum-based ChT. This could be due to 
the fact that NLR and PLR are associated to benefit from treatments administered after platinum ChT; therefore, 
Figure 2. Forest plot illustrating the results of univariable (A) and multivariable (B) analysis of covariates 
associated with the risk of disease progression in mTNBC.
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their effect may only emerge when evaluating OS as an endpoint. Alternatively, these parameters may be generally 
prognostic in HR+ BC, but not predictive of benefit from specific treatments. Based on our data, we are unable to 
discriminate between these two hypotheses.
Studies conducted in recent years have revealed a previously unrecognized complexity of the number and 
functional status of different immune system subpopulations35,36. For instance, circulating blood lymphocytes 
include phenotypically and functionally different cells, such as CD8+ cytotoxic lymphocytes, regulatory T cells 
and exhausted lymphocytes, whose balance can determine the predominantly antitumor or protumor activity 
of adaptive immunity35. In parallel, blood monocytes include both cells that differentiate into antitumor M1 
macrophages at the tissue level, and myeloid-derived suppressive cells (MDSCs) that exert pro-tumor effects by 
inhibiting the activity of antitumor T lymphocytes37. Coherently with a previous research in localized TNBC23, in 
this study we also found an association between the LMR and patient PFS, but this was weaker than in the case of 
NLR and PLR, and similar to the association between absolute lymphocyte counts and PFS. This finding suggests 
that monocytes may be poorly predictive of survival in mTNBC.
Investigating the potential association between specific immune cell populations and patient prognosis could 
reveal more reliable and predictive parameters to improve treatment selection in mTNBC. In this perspective, we 
recently started a prospective observational study to assess the role of baseline immunological parameters, as well 
as their on-treatment modifications, on the PFS of mTNBC patients receiving platinum-based ChT.
In this study, we did not find any significant difference in PFS duration between patients with or without 
BRCA1/2 germline mutations, which have recently emerged as associated with higher tumor response rates dur-
ing carboplatin ChT6. However, the number of subjects amenable to this analysis was too low, and larger stud-
ies are required to assess the independent predictive role of NLR/PLR and BRCA1/2 mutations on the PFS of 
mTNBC receiving platinum-based ChT.
Strengths of this study consist in the monocentric patient cohort, which guarantees more reproducible assess-
ment of tumor response and coherent collection of patient laboratory data by different investigators, as well as the 
homogeneity of ChT regimens used and the TNBC patient cohort. In particular, the fact that all TNBC patients 
received carboplatin-based ChT as first- or second-line treatment makes our results more robust compared to 
previously published data in patients treated with different regimens in different treatment lines. Weaknesses of 
our study consist in the retrospective design, the limited number of TNBC patients included in the analysis and 
the lack of data on tumor-infiltrating immune cells, which did not allow us to establish a direct, mechanistic link 
Figure 3. Kaplan-Meier curves of overall survival (PFS) of TNBC and HR+ mBC patients according to 
baseline NLR (A and C) and PLR (B and D).
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between peripheral blood parameters and immune cell populations in tumor microenvironment or directly infil-
trating the tumor. However, the NLR and PLR calculated at the initiation of platinum-based ChT may reflect the 
systemic inflammatory and immunological status much more reliably than immune cells detected in tumor speci-
mens biopsied/removed months/years before treatment administration. Moreover, the NLR and PLR could offer a 
more global picture of the immune contexture, thus circumventing the spatial heterogeneity in tumor-infiltrating 
immune cell populations.
In conclusion, the NLR and PLR are predictive of benefit from platinum-containing ChT specifically in 
mTNBC patients. They also confirm to have a generally prognostic role independently from tumor biology. If 
validated in larger prospective studies, these easy-to-measure parameters could be combined with emerging pre-
dictive biomarkers, such as germline or somatic BRCA 1/2 gene mutations, to improve the selection of mTNBC 
patients more likely to benefit from platinum-based ChT.
Methods
Study setting. This was a monocentric, retrospective study on patients with mTNBC treated between July 
2007 and July 2017 at Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy) with platinum-based ChT. 
Figure 4. Forest plot illustrating the results of univariable (A) and multivariable (B) analysis of covariates 
associated with the overall survival in mTNBC.
www.nature.com/scientificreports/
8ScIentIfIc RePoRTs |  (2018) 8:8703  | DOI:10.1038/s41598-018-27075-z
The study was approved by the Institutional Review Board of Fondazione IRCCS Istituto Nazionale dei Tumori 
(Milano, Italy). The study was performed in accordance to relevant guidelines and regulations. Patients alive at the 
time of data collection and/or analysis signed an informed consent for the use of their personal data for research 
purposes.
Eligibility criteria were: (1) age ≥18 years; (2) pathologically or cytologically confirmed diagnosis of unre-
sectable, locally recurrent or metastatic TNBC, as defined by ER <1% and PgR <1% expression at immunohis-
tochemistry (IHC) analysis and an IHC score for HER2 of 0, 1+, or 2+ with negative in situ hybridization (ISH); 
(3) ECOG performance status (PS) of 0–1; (4) treatment with one the following ChT schedules: carboplatin area 
under the concentration-time curve (AUC) of 2 plus paclitaxel 80 mg/m2, or carboplatin AUC 2 plus gemcitabine 
800 mg/m2, both given on days 1 and 8 of every-three weeks cycles; (5) availability of baseline (pre-treatment) 
absolute peripheral blood neutrophil, lymphocyte and platelet counts; (6) available information about previous 
treatment(s) for limited-stage or advanced disease; (7) available information on the date of disease progression 
and patient death; (8) absence of acute infections or documented bone marrow infiltration at the time of periph-
eral blood cell count assessment.
As a control population, we selected patients with HR+ HER2− mBC treated with the same platinum-containing 
regimens in the July 2007-July 2017 decade at our Institution.
All subjects fulfilling these criteria were evaluated, regardless of line of treatment for mBC.
Objectives. The main objective of the study was to investigate the potential association between baseline 
NLR/PLR and clinical outcome. The primary clinical endpoint was PFS, as defined as the time between treatment 
initiation and disease progression or death from any cause. OS was a secondary endpoint, and was defined as the 
time between treatment initiation and death from any cause.
Assessment of response. Response was assessed every 3 ChT cycles, but tumor re-evaluation was antici-
pated in patients with worsening symptoms or other signs suggestive of progressive disease (PD). Tumor response 
was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Patients with only 
superficial, measurable disease were evaluated also clinically by measuring lesion diameters every three weeks.
Evaluation of biomarkers. We collected data on absolute counts of peripheral blood neutrophils, lympho-
cytes, platelets and monocytes. We calculated the following parameters: (a) NLR by dividing neutrophil by lym-
phocyte counts; (b) PLR by dividing platelet by lymphocyte counts. As an exploratory analysis, we also assessed 
the lymphocyte-to-monocyte ratio (LMR). Blood parameters were evaluated before initiation of platinum-based 
ChT. Parameters measured within one month before the initiation of platinum-based ChT were considered 
acceptable, provided that the patient was not receiving any concomitant anticancer treatment. Patients whose 
blood parameters were measured more than one month before ChT initiation, or after having received the first 
dose of platinum-based ChT, were excluded from this study. As an exploratory analysis, we also evaluated the 
NLR and PLR before the administration of the third treatment cycle.
Genetic analysis. Analysis of BRCA1/2 germline mutations was carried out on the DNA extracted from 
peripheral blood leukocytes. All coding exons and flanking regions of BRCA1 and BRCA2 genes were sequenced 
through direct sequencing, followed in most cases by multiple ligation-dependent probe amplification (MLPA) 
to detect large genomic rearrangements. Identified genetic variants were classified according to the IARC 5-tier 
scheme, following the guidelines of the Evidence-based Network for the Interpretation of Germline Mutant 
Alleles (ENIGMA; http://enigmaconsortium.org/)38.
Statistical analysis. Patients’ characteristics were analysed by descriptive statistics. The χ2 or Fisher’s exact 
tests were used to assess the association between categorical variables, while linear correlation was used for con-
tinuous variables. PFS and OS were calculated according to the Kaplan-Meier method, and the log-rank test was 
used to compare survival between different patient populations. The impact of known prognostic factors on PFS 
was first assessed at univariate analysis. Covariates significantly associated with the risk of progression (p < 0.1) 
were then included in a Cox proportional hazard model to assess their independent association with survival. 
Based on previously published data, the following categorical covariates were tested: previous exposure to taxanes 
(yes vs no); visceral disease (yes vs no); the number of metastatic sites (1–2 vs >2); having received maintenance 
treatment (yes vs no)9. The type of chemotherapeutical agent combined with carboplatin (i.e. gemcitabine vs 
paclitaxel) was also tested as a covariate. All statistical analyses were performed using the software R (version 
3.3.2 (2016-10-31)), while the package “survival” was used for survival analyses. A p value of 0.05 was chosen as a 
threshold level for statistical significance.
Data availability. The datasets generated and/or analysed during the current study are available from the 
corresponding author on reasonable request.
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